Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: Preliminary report

R. Shapiro; M. L. Jordan; V. P. Scantlebury; J. J. Fung; C. Jensen; C. Vivas; J. McCauley; W. D. Irish; S. Mitchell; A. J. Demetris; P. Randhawa; A. Jain; A. Tzakis; T. R. Hakala; R. L. Simmons; T. E. Starzl

Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: Preliminary report

R. Shapiro, M. L. Jordan, V. P. Scantlebury, J. J. Fung, C. Jensen, C. Vivas, J. McCauley, W. D. Irish, S. Mitchell, A. J. Demetris, P. Randhawa, A. Jain, A. Tzakis, T. R. Hakala, R. L. Simmons, T. E. Starzl

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

FK 506 was used as a primary immunosuppressive agent in 125 cases of renal transplantation in a randomized trial comparing FK 506/prednisone with FK 506/azathioprine/prednisone. With a mean follow-up of 5.5 ± 2.5 months, there has been a 6-month actuarial patient survival of 99% and graft survival of 88%. There is no difference thus far between the two-drug and three-drug groups, although there may be less rejection and diabetes in the three-drug group. These results suggest that FK 506 is a useful immunosuppressive agent in kidney transplantation.

Original language	English
Pages (from-to)	669-672
Number of pages	4
Journal	Transplantation Proceedings
Volume	25
Issue number	1
State	Published - 1993
Externally published	Yes

Cite this

Shapiro, R., Jordan, M. L., Scantlebury, V. P., Fung, J. J., Jensen, C., Vivas, C., McCauley, J., Irish, W. D., Mitchell, S., Demetris, A. J., Randhawa, P., Jain, A., Tzakis, A., Hakala, T. R., Simmons, R. L., & Starzl, T. E. (1993). Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: Preliminary report. Transplantation Proceedings, 25(1), 669-672.

@article{a5cf9c0fc2cf4027a6a6ec592dc31d56,

title = "Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: Preliminary report",

abstract = "FK 506 was used as a primary immunosuppressive agent in 125 cases of renal transplantation in a randomized trial comparing FK 506/prednisone with FK 506/azathioprine/prednisone. With a mean follow-up of 5.5 ± 2.5 months, there has been a 6-month actuarial patient survival of 99% and graft survival of 88%. There is no difference thus far between the two-drug and three-drug groups, although there may be less rejection and diabetes in the three-drug group. These results suggest that FK 506 is a useful immunosuppressive agent in kidney transplantation.",

author = "R. Shapiro and Jordan, {M. L.} and Scantlebury, {V. P.} and Fung, {J. J.} and C. Jensen and C. Vivas and J. McCauley and Irish, {W. D.} and S. Mitchell and Demetris, {A. J.} and P. Randhawa and A. Jain and A. Tzakis and Hakala, {T. R.} and Simmons, {R. L.} and Starzl, {T. E.}",

year = "1993",

language = "English",

volume = "25",

pages = "669--672",

journal = "Transplantation Proceedings",

issn = "0041-1345",

publisher = "Elsevier USA",

number = "1",

}

Shapiro, R, Jordan, ML, Scantlebury, VP, Fung, JJ, Jensen, C, Vivas, C, McCauley, J, Irish, WD, Mitchell, S, Demetris, AJ, Randhawa, P, Jain, A, Tzakis, A, Hakala, TR, Simmons, RL & Starzl, TE 1993, 'Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: Preliminary report', Transplantation Proceedings, vol. 25, no. 1, pp. 669-672.

TY - JOUR

T1 - Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation

T2 - Preliminary report

AU - Shapiro, R.

AU - Jordan, M. L.

AU - Scantlebury, V. P.

AU - Fung, J. J.

AU - Jensen, C.

AU - Vivas, C.

AU - McCauley, J.

AU - Irish, W. D.

AU - Mitchell, S.

AU - Demetris, A. J.

AU - Randhawa, P.

AU - Jain, A.

AU - Tzakis, A.

AU - Hakala, T. R.

AU - Simmons, R. L.

AU - Starzl, T. E.

PY - 1993

Y1 - 1993

N2 - FK 506 was used as a primary immunosuppressive agent in 125 cases of renal transplantation in a randomized trial comparing FK 506/prednisone with FK 506/azathioprine/prednisone. With a mean follow-up of 5.5 ± 2.5 months, there has been a 6-month actuarial patient survival of 99% and graft survival of 88%. There is no difference thus far between the two-drug and three-drug groups, although there may be less rejection and diabetes in the three-drug group. These results suggest that FK 506 is a useful immunosuppressive agent in kidney transplantation.

AB - FK 506 was used as a primary immunosuppressive agent in 125 cases of renal transplantation in a randomized trial comparing FK 506/prednisone with FK 506/azathioprine/prednisone. With a mean follow-up of 5.5 ± 2.5 months, there has been a 6-month actuarial patient survival of 99% and graft survival of 88%. There is no difference thus far between the two-drug and three-drug groups, although there may be less rejection and diabetes in the three-drug group. These results suggest that FK 506 is a useful immunosuppressive agent in kidney transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0027419725&partnerID=8YFLogxK

M3 - Article

C2 - 7679836

AN - SCOPUS:0027419725

SN - 0041-1345

VL - 25

SP - 669

EP - 672

JO - Transplantation Proceedings

JF - Transplantation Proceedings

IS - 1

ER -

Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: Preliminary report

Abstract

Fingerprint

Cite this